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Introduction
About 5-10% of patients with FMF do not to colchicine
treatment to control inflammation. In these patients
anti-IL1 therapy seems to be effective in controlling
inflammation, although clinical trials are lacking. How-
ever, many patients on Anakinra experience side effects
including headache and injection-site reactions. How
Anakinra treatment influences quality-of-life (QoL) in
these patients is unknown.
Objectives
To investigate the effect of Anakinra on inflammation
and QoL in a family with a severe phenotype colchicine-
resistant FMF.
Patients and methods
Four sisters of Italian descent with homozygote M694V-
positive FMF, had an extraordinary phenotype with con-
tinuous inflammation, daily fevers, erysipelas-like skin
lesions and serositis. Colchicine was initiated in all
patient, but showed ineffective in controlling inflamma-
tion. Eventually, Anakinra was initiated. Before and dur-
ing treatment with Anakinra inflammatory parameters
(CRP, leukocyte-count, Serum amyloid A) were mea-
sured. One patient only started Anakinra after type AA
amyloidosis had developed leading to a renal replace-
ment therapy and renal transplantation. In the other
three patients QoL questionnaire (RAND-36) was
obtained, before and 4 weeks after start of Anakinra-
therapy. The study was approved by the local ethical
committee. Because of reimbursement was initially
declined, Anakinra was discontinued. Later, it could be
re-initiated. QoL questionnaires were obtained after
stopping and after re-initiation of Anakinra.
Results
During Anakinra treatment the CRP values were signifi-
cantly lower than without Anakinra (mean 3.7 mg/L vs
30 mg/L, p<0.001). The QoL improved significantly
after initiation of Anakinra in 5 out of 6 scales of the
RAND-36 (p<0.05). The QoL deteriorated after withdra-
wal of Anakinra to pre-treatment level and improved
again after re-initiation of Anakinra.
Conclusion
Here we show that Anakinra can effectively suppress inflam-
mation in a family with severe colchicine-resistant FMF.
This lead to a significant improvement in quality of life.
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